抵抗素
阿达姆斯
下调和上调
医学
MAPK/ERK通路
p38丝裂原活化蛋白激酶
血栓反应素
免疫印迹
脂肪因子
信号转导
内科学
内分泌学
细胞生物学
金属蛋白酶
基质金属蛋白酶
生物
胰岛素抵抗
生物化学
基因
胰岛素
作者
Caijun Liu,Hao Yang,Fei Gao,Xiang Li,Yan An,Jianru Wang,Anmin Jin
出处
期刊:Spine
[Lippincott Williams & Wilkins]
日期:2016-03-19
卷期号:41 (18): 1414-1420
被引量:47
标识
DOI:10.1097/brs.0000000000001556
摘要
Study Design. Rat nucleus pulposus (NP) cells were activated with resistin with or without p38 mitogen-activated protein kinase (MAPK) pathway inhibition. The expression of a disintegrin and metalloprotease with thrombospondin motif-5 (ADAMTS-5), which plays an important role in intervertebral disc degeneration (IDD), was determined. Objective. The aim of this study was to demonstrate whether resistin can influence the ADAMTS-5 expression and to further investigate the underlying mechanisms. Summary of Background Data. Obesity has been demonstrated to promote IDD, whereas the exact mechanism remains poorly understood. Resistin, as an important adipokine, is increased with obesity and has been shown to play pro-inflammatory and catabolic role in cartilage metabolism. However, the effect of resistin on the catabolic enzymes within NP cells remains unknown. Methods. We exposed NP cells to resistin, and the transcriptional activity, gene expression, and protein levels of ADAMTS-5 were measured by luciferase reporter assay, qRT-polymerase chain reaction, immunofluorescence, and western blot, respectively. The activation of p38 MAPK pathways was detected using western blot analysis. Results. Resistin had no effect on cell viability. Resistin increased ADAMTS-5 expression in rat NP cells time and dose dependently. The p38 MAPK signaling pathway was activated after exposure to resistin. Treatment with p38 inhibitor decreased the upregulation of ADAMTS-5 by resistin. Conclusion. The current study, for the first time, investigated the role of resistin in ADAMTS-5 regulation in IDD. These findings provide novel evidence supporting the causative role of obesity in IDD, which is important to develop novel preventative or therapeutic treatment in disc degenerative disorders. Level of Evidence: N/A
科研通智能强力驱动
Strongly Powered by AbleSci AI